Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy

Shun Saito, Takahiro Fujimaki, Watanalai Panbangred, Yasuhiro Igarashi, Masaya Imoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Prostate cancer is treated with androgen receptor (AR) antagonists but most patients experience disease progression after long-term treatment with these compounds. Therefore, new AR antagonists are required for patient follow-up treatment. In the course of screening for a new AR antagonist, we isolated the novel compounds antarlides A-E (1-5) from Streptomyces sp. BB47. Antarlides are mutually isomeric with respect to the double bond and have a 22-membered-ring macrocyclic structure. The full stereostructure of 1 was established by chemical modifications, including methanolysis, the Trost method, acetonide formation, and the PGME method. 1-5 inhibited the binding of androgen to ARs in vitro. In addition, 2 inhibited the transcriptional activity of not only wild-type AR but also mutant ARs, which are seen in patients with acquired resistance to clinically used AR antagonists. Therefore, antarlides are a potent new generation of AR antagonists that overcome resistance.

Original languageEnglish
Pages (from-to)2728-2732
Number of pages5
JournalAngewandte Chemie - International Edition
Volume55
Issue number8
DOIs
Publication statusPublished - 2016 Feb 18

Fingerprint

Androgen Receptor Antagonists
Androgen Receptors
propylene glycol methyl ether
Chemical modification
Androgens
Screening

Keywords

  • androgen receptor antagonists
  • cancer
  • drug resistance
  • natural products
  • NMR spectroscopy

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis

Cite this

Antarlides : A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy. / Saito, Shun; Fujimaki, Takahiro; Panbangred, Watanalai; Igarashi, Yasuhiro; Imoto, Masaya.

In: Angewandte Chemie - International Edition, Vol. 55, No. 8, 18.02.2016, p. 2728-2732.

Research output: Contribution to journalArticle

Saito, Shun ; Fujimaki, Takahiro ; Panbangred, Watanalai ; Igarashi, Yasuhiro ; Imoto, Masaya. / Antarlides : A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy. In: Angewandte Chemie - International Edition. 2016 ; Vol. 55, No. 8. pp. 2728-2732.
@article{3e135a7823644f61a28c5245005e30ea,
title = "Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy",
abstract = "Prostate cancer is treated with androgen receptor (AR) antagonists but most patients experience disease progression after long-term treatment with these compounds. Therefore, new AR antagonists are required for patient follow-up treatment. In the course of screening for a new AR antagonist, we isolated the novel compounds antarlides A-E (1-5) from Streptomyces sp. BB47. Antarlides are mutually isomeric with respect to the double bond and have a 22-membered-ring macrocyclic structure. The full stereostructure of 1 was established by chemical modifications, including methanolysis, the Trost method, acetonide formation, and the PGME method. 1-5 inhibited the binding of androgen to ARs in vitro. In addition, 2 inhibited the transcriptional activity of not only wild-type AR but also mutant ARs, which are seen in patients with acquired resistance to clinically used AR antagonists. Therefore, antarlides are a potent new generation of AR antagonists that overcome resistance.",
keywords = "androgen receptor antagonists, cancer, drug resistance, natural products, NMR spectroscopy",
author = "Shun Saito and Takahiro Fujimaki and Watanalai Panbangred and Yasuhiro Igarashi and Masaya Imoto",
year = "2016",
month = "2",
day = "18",
doi = "10.1002/anie.201510079",
language = "English",
volume = "55",
pages = "2728--2732",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Antarlides

T2 - A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy

AU - Saito, Shun

AU - Fujimaki, Takahiro

AU - Panbangred, Watanalai

AU - Igarashi, Yasuhiro

AU - Imoto, Masaya

PY - 2016/2/18

Y1 - 2016/2/18

N2 - Prostate cancer is treated with androgen receptor (AR) antagonists but most patients experience disease progression after long-term treatment with these compounds. Therefore, new AR antagonists are required for patient follow-up treatment. In the course of screening for a new AR antagonist, we isolated the novel compounds antarlides A-E (1-5) from Streptomyces sp. BB47. Antarlides are mutually isomeric with respect to the double bond and have a 22-membered-ring macrocyclic structure. The full stereostructure of 1 was established by chemical modifications, including methanolysis, the Trost method, acetonide formation, and the PGME method. 1-5 inhibited the binding of androgen to ARs in vitro. In addition, 2 inhibited the transcriptional activity of not only wild-type AR but also mutant ARs, which are seen in patients with acquired resistance to clinically used AR antagonists. Therefore, antarlides are a potent new generation of AR antagonists that overcome resistance.

AB - Prostate cancer is treated with androgen receptor (AR) antagonists but most patients experience disease progression after long-term treatment with these compounds. Therefore, new AR antagonists are required for patient follow-up treatment. In the course of screening for a new AR antagonist, we isolated the novel compounds antarlides A-E (1-5) from Streptomyces sp. BB47. Antarlides are mutually isomeric with respect to the double bond and have a 22-membered-ring macrocyclic structure. The full stereostructure of 1 was established by chemical modifications, including methanolysis, the Trost method, acetonide formation, and the PGME method. 1-5 inhibited the binding of androgen to ARs in vitro. In addition, 2 inhibited the transcriptional activity of not only wild-type AR but also mutant ARs, which are seen in patients with acquired resistance to clinically used AR antagonists. Therefore, antarlides are a potent new generation of AR antagonists that overcome resistance.

KW - androgen receptor antagonists

KW - cancer

KW - drug resistance

KW - natural products

KW - NMR spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=84958729571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958729571&partnerID=8YFLogxK

U2 - 10.1002/anie.201510079

DO - 10.1002/anie.201510079

M3 - Article

C2 - 26805525

AN - SCOPUS:84958729571

VL - 55

SP - 2728

EP - 2732

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 8

ER -